Jennifer A. Rymer, and L. Kristin Newby BTS 2017;2:

Slides:



Advertisements
Similar presentations
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
Advertisements

Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Date of download: 6/3/2016 From: Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type.
R3 JUNG Myounghwa/Prof.KIM Woo-Shik N Engl J Med 2012;366:
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Value of Platelet Reactivity in Predicting Response.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Non–ST-Segment Elevation Acute Coronary.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial of Estrogen Plus Progestin for Secondary.
From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:
From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):
Copyright © 2012 American Medical Association. All rights reserved.
Table 1. Baseline Characteristics of the 36,636 Study Subjects
Figure 1 Ischaemic endpoints
Copyright © 2011 American Medical Association. All rights reserved.
Volume 385, Issue 9985, Pages (June 2015)
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Copyright © 2004 American Medical Association. All rights reserved.
Clinical need for determination of vulnerable plaques
Copyright © 2007 American Medical Association. All rights reserved.
ELIGIBILITY: MRC/BHF Heart Protection Study
Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.
Risk Factors for Rehospitalization for Acute Coronary Syndromes and Unplanned Revascularization Following Acute Myocardial Infarction by Suzanne V. Arnold,
Myocardial Infarction (MI) or Heart Attack
Pathologic Findings 12/18/07
Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease  Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
Becker RC, et al. Lancet 2009;373:919-28
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis.
FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.
Figure 2 Absolute difference in seasonal peak
Rena Watanabe et al. BTS 2016;1:
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.
David J.A. Jenkins et al. JACC 2018;71:
Volume 385, Issue 9985, Pages (June 2015)
On Statin Treatment to Prevent Sepsis in Dialysis Patients
Dandan Wang et al. BTS 2018;3: Cardiomyocyte-Specific Knock-In miR-24 Ameliorates Ischemia/Reperfusion Injury (A) Quantitative polymerase chain.
The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation  David.
Improving Flexibility and Quality of Life for Your Patients: A Must?
Cause of death Treatment-arm events, % (n=45 054)
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
Baseline Characteristics of the Subjects*
SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.
Advantages of an early invasive approach in acute coronary syndromes
Lauren Brash et al. BTS 2018;3:
Baseline Characteristics by hs-CRP
Comparison of Baseline Characteristics by Primary End Point
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.
Genetic predisposition to CHD modifies the increased CHD risk associated with smoking (*) ORs adjusted for age, gender, total energy intake, alcohol intake,
Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,
FIELD: Primary outcome
Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.
Pamela E. Scott et al. JACC 2018;71:
Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.
Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Left Ventricular Mass at MRI and Long-Term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA) Left ventricular hypertrophy.
Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States  Ahmet Ergin, MD, PhD, MPH, Paul.
Cardiovascular Epidemiology and Epidemiological Modelling
Adjusted. ORs for outcomes by maintenance P2Y12 treatment
Presentation transcript:

Jennifer A. Rymer, and L. Kristin Newby BTS 2017;2:484-497 Cumulative Incidence Curves for CHD Death, MI, or Urgent Coronary Revascularization for Myocardial Ischemia for Treatment With Darapladib Versus Placebo (SOLID-TIMI 52, Phase 3) CHD = coronary heart disease; MI = myocardial infarction; SOLID-TIMI 52 = Stabilization of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52; other abbreviations as in Figure 2. Jennifer A. Rymer, and L. Kristin Newby BTS 2017;2:484-497 2017 The Authors

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.